Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer

1. Curigliano, G.
2. Pivot, X.
3. Cortés, J.
4. Elias, A.
5. Cesari, R.
6. Khosravan, R.
7. Collier, M.
8. Huang, X.
9. Cataruozolo, P.E.
10. Kern, K.A.
11. Goldhirsch, A.